Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services, as well as commercial manufacturing and sterile fill-finish services. It also provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.

Revenue projections:

Revenue projections for SYNGENE
Revenue projections for SYNGENE

With SYNGENE's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 1.63800
forwardPE 40.98241
debtToEquity 12.22600
earningsGrowth -0.02800
revenueGrowth 0.11000
grossMargins 0.74124
operatingMargins 0.23782
trailingEps 12.37000
forwardEps 16.85000

SYNGENE's current ratio, being 1.638, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, SYNGENE is well-equipped to meet its immediate financial obligations without any difficulties.
SYNGENE's low Debt-to-Equity ratio means the company is not over-leveraged, highlighting its conservative use of debt. This suggests reduced financial risk and a stable balance sheet, making SYNGENE a financially resilient company with lower exposure to debt-related pressures.
SYNGENE's low earnings and revenue growth suggest that the company's profits may shrink. This trend could indicate underlying financial struggles and pose challenges for SYNGENE's future profitability.
SYNGENE's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
SYNGENE's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for SYNGENE's financial growth.

Price projections:

Price projections for SYNGENE
Price projections for SYNGENE

Price projections for SYNGENE have steadily increased, reflecting growing optimism about the company's future. This trend suggests that analysts believe SYNGENE is well-positioned for continued success.

Insider Transactions:

Insider Transactions for SYNGENE
Insider Transactions for SYNGENE


28 SYNGENE transactions were recorded, when the market price was 808.6214250837054.There were no sell transactions throughout the period under consideration.The recent trend of more purchases than sales at Syngene International Limited's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for SYNGENE
Recommendations trend for SYNGENE


Analysts have shown a buy bias for SYNGENE, marking it as a favorable investment option. This could inspire investors to see SYNGENE as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.